Spouting Rock Asset Management, LLC Blueprint Medicines Corp Transaction History

Spouting Rock Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$46.9 - $66.0 $21,339 - $30,030	455 Added 8.77%	5,643 $283,000
Q2 2023 Aug 14, 2023	BUY	$42.2 - $66.37 $22,366 - $35,176	530 Added 11.38%	5,188 $327,000
Q1 2023 May 10, 2023	BUY	$37.97 - $50.0 $176,864 - $232,900	4,658 New	4,658 $209,000
Q3 2022 Nov 08, 2022	BUY	$49.93 - $77.7 $200,918 - $312,664	4,024 New	4,024 $265,000
Q3 2021 Nov 15, 2021	SELL	$80.98 - $109.47 $310,396 - $419,598	-3,833 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $36,009 - $43,935	435 Added 12.8%	3,833 $337,000
Q1 2021 May 17, 2021	BUY	$90.71 - $108.28 $308,232 - $367,935	3,398 New	3,398 $330,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Spouting Rock Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Spouting Rock Asset Management, LLC with notifications on news.